Register | Login
Intellectual Property Today
RFC Express - Document Management System
2013 Top Patent Firms
2013 Top Trademark Firms
Current Issue
_blank

Advertising Opportunities

Click Here

Email A Friend Back to Archived News


ImmunoCellular Therapeutics Receives Allowance of a New Patent on its Antibodies Targeting Pancreatic Cancer


Wednesday, March 17, 2010

Los Angeles, CA -- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance from the United States Patent and Trademark Office covering technology relating to monoclonal antibodies that bind to certain epitopes present on pancreatic cancers. This patent will broaden the Company’s proprietary intellectual property for ICT-109 and ICT-37, two of the Company’s monoclonal antibody product candidates.

ICT-109 and ICT-37 are humanized monoclonal antibodies that target small cell lung cancer and pancreatic cancer. ICT-109 antibody specifically binds to certain glycosylations (sugar structures) present on CEA-CAM6 and CEA-CAM5, which are highly expressed on malignant cells, while ICT-37 specifically targets CEA-CAM5.

"This is a very good news for us," commented Dr. Manish Singh, PhD., President and CEO of IMUC. "The notice of allowance further strengthens ImmunoCellular’s intellectual property portfolio." The Company also has 7 granted US patents and 8 issued international patents and over 25 pending patents.

In preclinical in-vitro testing, ICT-109 has been demonstrated to bind to 100% of pancreatic cancer tissues and has demonstrated an ability to detect the antigen in the blood sample of the patients. By combining ICT-109 with additional biomarkers, it may be possible to detect pancreatic cancer and lung cancers during their early stage, which usually results in longer survival times for those patients.

About ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company has completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter phase II study of ICT-107 in the second half of 2010. The Company’s "off the shelf" therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the second half of 2010. IMUC has entered into a research and license option deal with the Roche Group for one of the Company’s monoclonal antibody product candidates for the diagnosis and treatment of ovarian cancer and multiple myeloma, which provides for potential licensing and milestone payments of $32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery to target cancer stem cells. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the risk that patents issued for IMUC's monoclonal antibody product candidates may not be enforceable or may not provide commercially significant protection for these candidates; the need to confirm preliminary pre-clinical data for IMUC's lead monoclonal antibody and other monoclonal antibody product candidates; the risks associated with pre-clinical and clinical development of monoclonal antibody and other product candidates; the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; and the potential inability to secure corporate partners or licensees for development of the monoclonal antibody product candidates. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K, IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



Back to Archived News
Looking for...

  © Copyright 2013 Intellectual Property Today
Download Adobe Reader for free